Compare Payoneer Global Inc (PAYO) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs Revvity Inc — how do they compare? Payoneer Global Inc trades at $7.15 (market cap $2.43B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 7× Payoneer Global Inc's market cap, and Revvity Inc pays a 0.18% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 61 Days and Revvity Inc for 12 Days on average.
| PAYO | RVTY | |
|---|---|---|
Market Cap | $2.43B | $16.98B |
Volume | 1,342,701 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $7.18 | $157.36 |
52-Week Low | $4.27 | $82.26 |
Typical Hold Time | 61 Days | 12 Days |
Enterprise Value | $2.17B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.14, down 0.28% on the day, with a bullish technical outlook supported by moving averages. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but maintains strong revenue growth and a 78% gross margin. Recent news highlights the renewal of its partnership with Etsy through 2029 and ongoing acquisition discussions with Nuvei.
The stock presents a mixed outlook: analyst consensus is 60% buy with no sell ratings, but elevated P/E of 51.18 and recent earnings misses pose valuation and execution risks. The pending acquisition adds uncertainty, while expansion into India offers growth potential. Investors should weigh strong fundamentals against high expectations and integration challenges.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
